GlassScriptPhysician profile
Timothy W Nush
NPI 1316160328
$4,281.34
in general payments reported to CMS, 2019-2025
38 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $130 · 2021: $494 · 2022: $896 · 2023: $718 · 2024: $992 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.15 | 2021-2025 | |
| Novo Nordisk INC | $695.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $346.86 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $268.93 | 2019-2023 | Trintellix |
| Lilly USA, LLC | $267.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $245.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $226.86 | 2021-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Amgen INC. | $199.19 | 2019-2025 | Otezla, Repatha, Otezla |
| Jazz Pharmaceuticals INC. | $198.69 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $137.37 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.77 | 2023-2025 | Caplyta |
| Insulet Corporation | $82.82 | 2024-2025 | Omnipod |
| Dexcom, INC. | $69.20 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $64.01 | 2024-2025 | Freestyle Libre 3 |
| Biogen, INC. | $59.24 | 2022-2025 | Zurzuvae |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Nush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.